At the Ebola Coordination center in Mubende, Dr. Abdou Salam Gueye the WHO Regional Emergency Director in Africa, met with the Mubende #EVD outbreak Coordination team in Mubende. The WHO Announced that the meeting of ambassadors is committed to supporting efforts to stop the Ebola outbreak. He reiterated that all efforts should bring on board community members and actors to take their space in the fight.
Deputy Incident Commander Mr. Atek Kagirita briefed the WHO representative on the progress of interventions taking place and thanked him for taking off time to come and see for himself the progress taking place. “This means a lot for us at the center of the Ebola fight, and we are doing all we can to make sure that this outbreak is contained without spreading any further,” he said.
The meeting was attended by Mubende District Leadership, the EVD National response team, and partners in the fight against Ebola, including included WHO, CDC, Baylor-Uganda, and IDI, among others,
On 20th September 2022, the health authorities in Uganda declared an outbreak of Ebola after a case was confirmed in Madudu sub-county, Mubende district, central Uganda.
CDC, through Baylor Uganda, has contributed to the Ebola fight by providing technical staff to support coordination and surveillance activities and doctors for case management. Other support includes orientation of contact tracers and VHTS on contact tracing and supporting teams to do contact tracing in the affected communities. Baylor collaborated with other CDC-funded partners(IDI, METS and MildMay) to train over 1000 VHTs in the Mubende district.
CDC/Baylor-Uganda has also provided response logistics Including, Vehicles for contact tracing, laptops, Phones for alert management, routers for internet for the situation room, furniture, stationery, and thermometers for daily monitoring during follow-up of contacts.
Baylor also volunteered to provide case management services. This boosted diagnosis and treatment of cases, a very big intervention in making sure that victims survive.